Event-Free Survival Analysis Of The Prospectively Randomized Phase Iii Etna Study With Neoadjuvant Nab-Paclitaxel (Nab-P) Versus Paclitaxel (P) Followed By Anthracycline Regimens In Women With Her2-Negative High-Risk Breast Cancer.

JOURNAL OF CLINICAL ONCOLOGY(2019)

引用 13|浏览76
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要